◆ mixed
Impact
PhaseFiled/PDUFA (BLA under FDA review); also multiple ongoing Phase 3 trials
Time to marketIf approved, potential US launch in late 2026 or early 2027. Already approved in China (May 2024).
ivonescimab Updated Jun 30
What to watch
The November 14 PDUFA is the defining event. The HARMONi global trial showed statistically significant PFS but OS missed the pre-specified threshold, an unusual situation that creates binary risk on approval odds. Watch for an FDA Advisory Committee date (if scheduled) as a pre-decision signal. Also watch HARMONi-3 final PFS readout (2H 2026) as a secondary catalyst. The $500M June offering diluted existing holders but extended the cash runway, and the massive insider buying (~$100M from co-CEOs at ~$13.12) signals conviction at current levels.
Bull case
- First-in-class PD-1/VEGF bispecific, the only one to complete Phase 3 validation globally, with a potential mechanistic advantage over combining two separate antibodies
- HARMONi-6 delivered statistically significant OS benefit (HR=0.66, 34% risk reduction) presented at ASCO 2026 plenary, proving the drug can beat PD-1+chemo
- Massive insider buying: co-CEOs Robert Duggan and Mahkam Zanganeh purchased ~$100M total at ~$13.12/share on June 12, 2026, a strong conviction signal near the 52-week low
Bear case
- OS data is mixed and controversial: the global HARMONi trial's OS missed the pre-specified threshold, HARMONi-2's OS (vs Keytruda monotherapy) was negative, and only HARMONi-6 (China-only data) showed positive OS
- Interim PFS analysis of HARMONi-3 (the pivotal US registration trial vs Keytruda+chemo) missed the early statistical bar, raising questions about whether the drug can beat the current standard of care in Western patients
- $500M dilutive public stock offering announced June 9, 2026 sent shares to a 52-week low of $12.55; existing holders were significantly diluted